Compare MTZ & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | WST |
|---|---|---|
| Founded | 1929 | 1923 |
| Country | United States | United States |
| Employees | N/A | 10800 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 25.8B |
| IPO Year | 2005 | 2004 |
| Metric | MTZ | WST |
|---|---|---|
| Price | $373.43 | $365.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 7 |
| Target Price | ★ $339.47 | $325.86 |
| AVG Volume (30 Days) | ★ 1.1M | 674.9K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 146.12 | 1.49 |
| EPS | 0.77 | ★ 1.92 |
| Revenue | ★ $14,299,171,000.00 | $2,886,900,000.00 |
| Revenue This Year | $20.38 | $6.76 |
| Revenue Next Year | $10.18 | $6.22 |
| P/E Ratio | $486.13 | ★ $190.59 |
| Revenue Growth | ★ 16.22 | 1.95 |
| 52 Week Low | $160.08 | $206.80 |
| 52 Week High | $441.43 | $367.66 |
| Indicator | MTZ | WST |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 78.53 |
| Support Level | $369.04 | $253.53 |
| Resistance Level | $438.66 | N/A |
| Average True Range (ATR) | 19.24 | 7.33 |
| MACD | 1.30 | 2.68 |
| Stochastic Oscillator | 20.61 | 95.80 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.